- Home
- ABTS vs HCWB Comparison
ABTS vs HCWB Comparison
Compare ABTS & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | HCWB |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABTS | HCWB |
|---|---|---|
| Price | $1.18 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.6K | ★ 748.2K |
| Earning Date | 10-15-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | N/A | $12,215.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.86 |
| 52 Week High | $9.03 | $23.94 |
Technical Indicators
Market Signals| Indicator | ABTS | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 25.82 |
| Support Level | $1.14 | $0.86 |
| Resistance Level | $1.30 | $1.73 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 14.36 | 0.06 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a bitcoin mining company. The Company operates self-owned and hosted bitcoin mining facilities in Tennessee, United States.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.